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Abstract
An increasing amount of data supports an inverse association between statin use and cancer risk. 
The findings for prostate cancer, particularly advanced disease, are the most promising of all 
cancers studied. Use of these agents seems to also be associated with improved prostate-cancer-
specific survival, particularly in men undergoing radiotherapy, suggesting usefulness of statins in 
secondary and tertiary prevention. Some study results might be influenced by increased PSA 
screening and health-conscious behaviour in statin users but these factors are unlikely to 
completely account for observed beneficial effects. The epidemiological evidence is supported by 
preclinical studies that show that statins directly inhibit prostate cancer development and 
progression in cell-based and animal-based models. The antineoplastic effect of statins might arise 
from a number of cholesterol-mediated and non-cholesterol-mediated mechanisms that affect 
pathways essential for cancer formation and progression. Understanding these mechanisms is 
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instrumental in drug discovery research for the development of future prostate cancer therapeutics, 
as well as in designing clinical trials to test a role for statins in prostate cancer prevention. 
Currently, sufficient data are lacking to support the use of statins for the primary prevention of 
prostate cancer and further research is clearly warranted. Secondary and tertiary prevention trials 
in men who have been diagnosed with prostate cancer might soon be performed.
Statins are a class of medications that effectively lower serum cholesterol levels by 
inhibiting 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase, which is the 
rate-limiting enzyme for cholesterol synthesis in the liver. Statins are becoming one of the 
most commonly prescribed medications in the USA, owing to the epidemic proportions of 
hyperlipidaemia in this country1. In 2012, more than one in four US adults aged ≥40 years 
reported using statins; simvastatin and atorvastatin were the two most commonly used 
agents (42% and 20% of all statin users, respectively)2. Unequivocal evidence exists that 
statins reduce the number of adverse cardiovascular events associated with 
hyperlipidaemia3, but during the past decade several reports have highlighted the potential of 
statins in chemoprevention of other diseases4–11. For example, statin use has been linked to 
reduced risk of several cancer types. The most promising data relate to the prevention of 
prostate cancer — in particular advanced disease6–11. However, advocating that all men start 
taking statins as a chemopreventive measure against prostate cancer would currently be 
premature, as not all data agree on the potential benefits of statins, especially in reducing the 
risk of prostate cancer of any stage (referred to as total prostate cancer)12,13. In this Review, 
we present the current evidence supporting and opposing a role for statins in the 
chemoprevention of prostate cancer. We review cell-based and animal-based pre-clinical 
studies that examined the molecular mechanisms of inhibitory effects of statins on prostate 
cancer growth and examine the most current data from studies in humans on associations 
between statin use and prostate cancer, with an emphasis on the accumulating evidence that 
supports an effect of statin use in preventing advanced prostate cancer and prostate cancer 
progression. We also discuss the current gaps in our understanding of how statins might 
modify prostate cancer risk, which require further work to better guide future research and 
funding strategies.
Statin medications: the basics
The ability of statins to reduce the number of adverse cardiovascular events associated with 
hyperlipidaemia by lowering total serum cholesterol and LDL cholesterol levels is well 
established. The underlying mechanism is based on restricting cholesterol synthesis in the 
liver via inhibition of the rate-limiting hepatic HMG-CoA reductase3. Statins can be 
classified as either hydrophilic or lipophilic, depending on their solubility14 (TABLE 1). 
Hydrophilic statins are more hepatoselective than lipophilic statins, as they are actively 
transported into the liver by members of the organic anion transporting poly-peptide family 
(also known as OATPs). By contrast, lipophilic statins enter the liver by passive diffusion. 
Relative to hydrophilic statins, lipophilic statins are taken up more easily by nonhepatic 
tissues that do not express dedicated transporters, such as the prostate15. Hence, lipophilic 
stat-ins have been hypothesized to have a greater influence on the prostate than hydrophilic 
statins, but this theory has not been corroborated by observational studies of statin use and 
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prostate cancer risk (TABLE 2), in part because the number of men taking hydrophilic 
statins was low6,16–18.
Statins are generally well tolerated, with the most common adverse effects being hepatic 
dysfunction and muscle myopathies. A meta-analysis of 35 clinical trials in patients with 
hyperlipidaemia receiving a statin or a placebo drug concluded that statin therapy is 
associated with a small excess risk of hepatic dysfunction but not of myalgias, 
rhabdomyolysis or elevation of creatine kinase levels, which is a marker of myopathy19. 
Another meta-analysis of 13 clinical trials showed that statin use was associated with a 
slightly elevated risk of new-onset diabetes, but this risk was offset by the cardiovascular 
benefits of statins20. Owing to the good efficacy and safety profile of statins, following the 
FDA approval of lovastatin in 1987, market introduction of six other statins was not 
surprising and statin use has been increasing continuously21,22 (FIG. 1). Interestingly, 
cardiovascular benefits of taking statins have also been observed in users who do not have 
elevated cholesterol levels23, suggesting that statin use has non-cholesterol-mediated effects. 
These findings of pleiotropic effects of statins lend support to the rationale to examine 
whether statins might modify cancer risk.
Interestingly, early observations in rodents indicated that cholesterol-lowering drugs could 
cause cancer, albeit at doses exceeding those administered to humans24. Similar results in 
human populations were subsequently attributed to reverse causality, caused by 
accumulation of cholesterol from the serum in tumours, resulting in a drop in serum 
cholesterol levels25. Since the publication of these findings, the majority of epidemiological 
data have indeed shown a protective effect of statins against cancer4–11.
Mechanisms of prostate cancer prevention
As evidence from studies in humans that supports a role for statins in modifying prostate 
cancer risk is accumulating, investigation of the underlying molecular mechanisms, using 
established cell-based and animal-based preclinical models becomes essential. Much data 
from these models have already been published, demonstrating that statins can inhibit 
prostate cancer growth through cholesterol-mediated and non-cholesterol-mediated 
mechanisms that affect many pathways essential for cancer formation and progression. 
Specifically, statins have been shown to inhibit prostate cancer inflammation26, 
angiogenesis27, cell proliferation28, migration and/or adhesion29 and invasion30, and to 
promote apoptosis31. In addition, inhibition of HMG-CoA reductase by stat-ins lowers the 
concentration of mevalonate (FIG. 2) and, consequently, levels of downstream, isoprenylated 
intermediates believed to be essential in signalling pathways that support cancer formation 
and progression32.
Cholesterol-mediated pathways
A positive correlation between cholesterol accumulation in prostatic tissues and the presence 
of prostate cancer was already reported in 1981 (REF. 33). Several mechanisms have since 
been shown to contribute to dysregulation of cholesterol homeostasis in prostate tumours. 
One study found that hypermethylation of the ABCA1 promoter resulted in reduced 
expression of the encoded cholesterol efflux transporter, decreased cholesterol efflux rates 
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and elevated intracellular cholesterol levels in prostate cancer cell lines, and that the 
presence of this epigenetic alteration was associated with high-grade prostate cancer34. In 
addition, the mTOR pathway is important in regulating sterol-regulatory-element-binding 
proteins (also called SREBPs), which are transcription factors that control lipid and 
cholesterol homeostasis35. One study reported that intracellular accumulation of cholesteryl 
ester in lipid droplets was driven by loss of expression of the tumour suppressor PTEN and 
subsequent activation of the PI3K–AKT–mTOR signalling pathway, and that intracellular 
accumulation of cholesteryl ester was associated with high-grade prostate cancer in 
humans36.
One of the major cholesterol-mediated mechanisms through which statins inhibit tumour 
growth involves specialized cholesterol-rich regions of the cell membrane known as lipid 
rafts37. These domains facilitate membrane-initiated signalling events in the cell through 
compartmentalization of signalling pathways, which can enhance tumour growth. Cell 
signalling pathways implicated in prostate cancer development and progression that might 
be affected by lipid raft cholesterol composition include pathways involving the androgen 
receptor38, the epidermal growth factor receptor (EGFR)39 and the luteinizing hormone 
receptor40. Statins, through their effect on intracellular cholesterol homeostasis, are thought 
to disrupt the organization of lipid rafts and, thus, interfere with these or other downstream 
intracellular signalling pathways41.
The EGFR pathway is one example of the direct effect that reduced cholesterol content of 
the rafts can have on membrane-initiated signalling. EGFR is a cell-membrane-bound 
receptor that associates with lipid rafts in prostate cancer cells39. EGFR activation leads to 
activation of protein kinase B (AKT, encoded by AKT1), which promotes the growth of 
several solid tumour types, including prostate cancer42. Treatment of prostate cancer cells 
with cholesterol binders can disrupt lipid raft organization and interfere with EGFR 
signalling39.
In addition, one study found that activation of cholesterol efflux through treatment with a 
liver X receptor agonist induced apoptosis through disruption of lipid rafts and subsequent 
downregulation of AKT signalling in LNCaP in vitro and in vivo models43. Other signalling 
pathways implicated in the development of prostate cancer and castration resistance, such as 
IL-6-activated JAK–STAT3 (Janus kinase–signal transducer and activator of transcription 3) 
signalling, have also been found to be affected by lipid raft organization and are, therefore, 
potentially influenced by lipid raft cholesterol concentrations44. The importance of 
cholesterol in prostate cancer development has also been seen in a mouse model. In one 
study, mice were either fed a high-fat, high-cholesterol diet or a low-fat, low-cholesterol 
diet45. After subcutaneous injection of LNCaP cells, elevated cholesterol levels in the serum 
of mice that were fed the high-fat, high-cholesterol diet promoted xenograft tumour growth 
and reduced apoptosis, in part by increasing activity of AKT. Inhibition of cholesterol 
synthesis with a statin disrupted lipid rafts in the tumours and induced apoptosis via 
attenuation of AKT signalling45.
In addition, cholesterol levels might also affect prostate cancer development via androgen 
signalling pathways, as cholesterol is the precursor of androgens. Lowering cholesterol 
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levels using statins might reduce prostate cancer growth by reducing serum or intratumoural 
levels of androgens. However, the effect of statins on serum androgen levels is unclear. Some 
studies have suggested that statins reduce serum testosterone levels46–48, but these 
reductions were small or caused by statin doses that were higher than commonly used in 
clinical practice. Other observational studies49,50 and two clinical trials51,52 found no 
association between statin use and serum androgen levels. A study in 1,812 men in the 
Boston Area Community Health Survey cohort of which 237 men were statin users found no 
association between statin use and serum androgen levels53. Emerging evidence suggests 
that intratumoural levels of androgens remain high even when castrate levels of androgens 
are reached in the serum of patients with prostate cancer, possibly owing to de novo 
androgen synthesis in the tumour cell54–56. Thus, statins might conceivably be able to lower 
intratumoural androgen levels by lowering intratumoural cholesterol levels. Indeed, a study 
in noncastrated mice with hyper-cholesterolaemia induced by a high-fat, high-cholesterol 
diet found increased intratumoural levels of androgens in LNCaP xenografts without an 
effect on androgen levels in serum, suggesting that hypercholesterolaemia induces 
intratumoural de novo steroidogenesis57.
Non-cholesterol-mediated pathways
Statins inhibit the conversion of HMG-CoA to mevalonate, thereby reducing cellular 
mevalonate concentrations. Mevalonate is a precursor for a class of compounds called 
isoprenoids, such as farnesyl pyrophosphate and geranyl pyrophosphate (FIG. 2). Farnesyl 
pyrophosphate and geranyl pyrophosphate facilitate the recruitment of signalling proteins, 
such as G-proteins of the Ras and Rho superfamilies, by bridging their attachment to the 
plasma membranes, where their signalling activities can promote prostate cancer cell 
survival and proliferation58,59. Thus, statins, by reducing mevalonate and downstream 
isoprenoids, might inhibit cancer cell proliferation.
Furthermore, statins seem to directly induce apoptosis in cancer cells independently of their 
effect on cholesterol levels32. For example, in prostate cancer, statins can inhibit cyclin-
dependent kinase 2 and stimulate cell cycle arrest60, or activate specific proteases that 
themselves can activate apoptosis61. Statins also have direct anti-inflammatory and 
antiangiogenic properties that, conceivably, might also inhibit cancer growth and 
progression32. One study in a cohort of men undergoing radical prostatectomy found that 
statin users were 69% less likely to have inflammation within their prostate tumours than 
nonusers (P=0.047), as assessed by pathological evaluation of tumour sections stained with 
haematoxylin and eosin62.
Epidemiological evidence
In the past few years, interest in the use of statins for prostate cancer prevention has 
increased63. It has even been suggested in a study by Colli and Amling64 that stat-ins might 
be partially responsible for the steep decline in the prostate cancer death rate in the USA 
during the past 15 years (see the American Cancer Society Cancer Facts & Figures 2016), as 
it paralleled the market introduction and distribution of statins (FIG. 1). Evaluation of 
epidemiological studies and secondary analyses of randomized controlled trials seems to 
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show that most evidence supports the hypothesis that statin use reduces prostate cancer risk, 
with the strongest evidence to date supporting that statins might selectively lower the risk of 
advanced prostate cancer. In addition to data supporting an inverse association between 
statin use and risk of advanced prostate cancer, evidence also exists that statins might affect 
prostate cancer progression at multiple stages of the disease course, including biochemical 
recurrence after primary therapy, development of castration resistance following androgen 
deprivation therapy, as well as prostate cancer-specific mortality (FIG. 3).
Total prostate cancer
More than 30 observational studies have examined the link between statin use and total 
prostate cancer risk with encouraging though conflicting results (TABLE 2). A number of 
case-control studies reported no associations7,16,65–67, but three reported an elevated risk of 
total prostate cancer in statin users10,68,69. The investigators of one of these studies 
suggested that the positive association between statin use and total prostate cancer risk is 
potentially attributable to bias arising from increased surveillance in men initiating statin 
treatment10. Indeed, one study in Finland found that the elevated prostate cancer risk in new 
statin users disappeared with increasing duration of statin use, supporting this possible 
explanation69. Other case-control studies have reported inverse associations between statin 
use and risk of total prostate cancer6,18,70, including one study in 4,204 men undergoing 
prostate biopsy that reported a significant 8% reduced risk of total prostate cancer in statin 
users in comparison with nonusers (RR 0.92; 95% CI 0.85–0.98)70. The largest population-
based case-control study to date, a Danish study that included >40,000 patients with any 
stage of prostate cancer and >200,000 controls, reported a significant 6% reduction in risk of 
total prostate cancer in statin users (adjusted OR 0.94; 95% CI 0.91–0.97)18.
These case-control studies reported varying findings for associations between statin use and 
total prostate cancer risk, but a number of cohort studies have also been conducted. A 
retrospective study of data from a cohort of >55,000 men in the Veterans Affairs New 
England Healthcare System found that statin users were 31% less likely to be diagnosed 
with total prostate cancer than men who did not use statins71. Two prospective cohort studies 
including 6,692 and 634 men taking statins and undergoing PSA screening found a 25% and 
64% reduced prostate cancer risk, respectively72,73. A retrospective cohort study in Israel of 
37,645 men taking statins found a 74% reduced risk of total prostate cancer in long-term 
statin users, defined as >5 years of statin use, in comparison with nonusers74. Other studies 
found weaker but still inverse associations between statin use and total prostate cancer 
risk75,76, including a population-based study in Washington, USA, that found that statin 
users had a nonsignificant 12% lower prostate cancer risk17.
Despite these promising data, other observational studies found no link between statin use 
and total prostate cancer risk, including a secondary analysis of a randomized trial in men 
with a negative prostate biopsy who underwent repeat biopsies at 2 years and 4 years77, in 
addition to several cohort studies5,8,9,11,78–82. Overall, individual case-control and cohort 
studies had conflicting findings, but the most recent meta-analysis of these studies from 
2012 reported a significant 7% reduction in risk of total prostate cancer in statin users in 
comparison with nonusers (P= 0.03)83.
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Three meta-analyses of randomized controlled trials of statin use for the primary and 
secondary prevention of adverse cardiovascular outcomes reported no association between 
statin use and total prostate cancer risk84–86. However, trial participants do not represent the 
general population. For example, all trials of statin use incorporated dietary interventions in 
both statin and placebo groups and all trial participants had a history of cardiovascular 
disease3. Furthermore, although the most commonly used statin in the USA is simvastatin2 
(TABLE 1), participants in the majority of clinical trials were randomized to receive 
pravastatin, which inhibits HMG-CoA reductase more weakly than simvastatin and has 
reduced cholesterol-lowering efficacy87. Finally, randomized controlled trials have relatively 
short follow-up periods: the median follow-up duration was 4.8 years for the 27 statin trials 
performed to date84. Together, these factors could explain differences in associations 
between statin use and total prostate cancer risk reported by observational studies and 
randomized trials.
Advanced prostate cancer
Overall, the data from studies examining associations between statin use and total prostate 
cancer are inconclusive, with the majority of studies showing no effect of statin use on total 
prostate cancer risk. However, increasing data indicate that statin use might selectively lower 
the risk of advanced prostate cancer (defined using varying levels of Gleason grade, clinical 
stage or a combination of both variables; TABLE 2).
Six large, prospective studies all found that statin users had a reduced risk of advanced 
prostate cancer without any reduction, or with an attenuated reduction, in total prostate 
cancer risk8,9,11,76,80,82. In all six studies, bias was minimized by controlling for potential 
confounding variables, for example, concomitant diseases, such as diabetes, use of 
antidiabetic drugs or other treatments and cardiovascular risk factors that are associated with 
prostate cancer risk, such as age, race and body mass index.
In a report from The Health Professionals Follow-up Study, data on cholesterol-lowering 
drug use for the period 1990–2002 from 34,989 men without a cancer diagnosis in 1990 
were analysed8. Statin use was significantly associated with a 49% reduced risk of advanced 
prostate cancer (RR 0.51; 95% CI 0.30–0.86) and a 61% reduced risk of metastatic or fatal 
prostate cancer (RR 0.39; 95% CI 0.19–0.77), but it was not associated with a reduced risk 
of total prostate cancer. In men who took statins for ≥5 years, the risk of advanced prostate 
cancer was significantly reduced by 74% (RR 0.26; 95% CI 0.08–0.83). Investigators of 
another prospective cohort, using data from the Cancer Prevention Study II Nutrition Survey 
(n= 55,454)9, found that men who took statins for ≥5 years had a 40% reduced risk of 
advanced prostate cancer but these findings were only just statistically significant (RR 0.60; 
95% CI 0.36–1.00) and did not reach significance in a follow-up analysis of this data-set80. 
Analyses of data from the California Men’s Health Study (n= 69,047)11, Southern 
Community Cohort Study (n = 32,091)76 and Kaiser Permanente Medical Care Program (n= 
2,097,474)82 found 20%, 38% and 17% reductions, respectively, in the risk of advanced 
prostate cancer among statin users; however, only the findings from Kaiser Permanente, the 
largest of these studies, were statistically significant (HR 0.83; 95% CI 0.72–0.96).
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Three small prospective studies have also been conducted, one of which found a 75% 
significantly reduced risk of advanced prostate cancer among daily statin users (HR 0.25; 
95% CI 0.11–0.58)73; findings of the other two studies were not significant81,88. A large 
retrospective cohort study71 that included men in the Veterans Affairs New England 
Healthcare System found a significant 60% reduction in risk of advanced prostate cancer 
among statin users (HR 0.40; 95% CI 0.24–0.65), but results from two other retrospective 
cohorts were not significant17,75.
Among published case-control studies, some reported no associations between statin use and 
risk of advanced prostate cancer7,65,66,68,69,89, but one small study6 and two large 
studies70,18 reported a significantly reduced risk of advanced prostate cancer in statin users 
(76%, 24% and 10%, respectively).
In summary, despite some contradicting reports, the majority of evidence supports an inverse 
association between statin use and risk of advanced prostate cancer. This finding is also 
demonstrated by the most recent meta-analysis, conducted using data from 27 observational 
studies published before 2012, which found that statin use was associated with only a 
modest reduction in total prostate cancer risk (7%; P = 0.03) but a more pronounced 
reduction in advanced disease risk (20%; RR 0.80; 95% CI 0.70–0.90; P<0.001) 83. Eight 
studies were published in 2012 or later18,74–77,81,88,90 and were, therefore, not included in 
this meta-analysis. Seven of these studies did not find statin use to be associated with 
reduced risk of advanced prostate cancer74–77,81,88,90. However, the study18 including the 
highest number of men with advanced prostate cancer of all studies to date (n = 12,412) 
reported a 10% significantly reduced risk of advanced prostate cancer in statin users (OR 
0.90; 95% CI 0.85–0.96), in line with the findings of the meta-analysis83.
Prostate cancer mortality
Understanding associations between statin use and prostate-cancer-specific mortality is 
important, as not all men with advanced prostate cancer die from their disease. An analysis 
of 1,001 men with prostate cancer of whom 289 men were statin users reported a hazard 
ratio of 0.19 (95% CI 0.06–0.56) for prostate-cancer-specific death in statin users compared 
with nonusers91. A registry-based study in a Danish population of 27,752 men with prostate 
cancer of whom 10,542 died of this disease, and who commenced statin use before diagnosis 
of any type of cancer, found that statin users had significantly lower prostate-cancer-specific 
mortality than nonusers (HR 0.81; 95% CI 0.75–0.88)92. A study that had been designed to 
assess the association between β-blocker use and prostate-cancer-specific mortality and 
analysed use of statins as a potential confounding factor found that statin use was inversely 
associated with lethal prostate cancer among 3,561 men with the disease with a median 
follow-up period of 39 months (HR 0.70; 95% CI 0.56–0.88; P= 0.03)93. Finally, an analysis 
of a population-based electronic database in the UK, containing data from 11,772 men with 
prostate cancer and 1,791 deaths from prostate cancer during a mean follow-up period of 52 
months, found that use of statins was associated with a lower risk of death from prostate 
cancer. The reduction in risk was larger in men who had commenced statin use before 
prostate cancer diagnosis (HR 0.55; 95% CI 0.41–0.74) compared with those who started 
taking statins after diagnosis (HR 0.82; 95% CI 0.71–0.96)94.
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Statin use and PSA levels
PSA testing is the most widely used method for prostate cancer screening. If statin use 
affects PSA levels, a systematic bias would be inherent in all studies that evaluated 
participants with PSA-based prostate cancer diagnoses (TABLE 2). Indeed, a pilot study in 
15 men demonstrated that statin use caused a 42% decline in PSA levels over a period of 5 
years95.
One cross-sectional study in 323,426 men aged ≥65 years who had a screening PSA test in 
2003 investigated how statin use affects PSA levels at the time of prostate cancer screening. 
Statin use was associated with a reduced probability of having an abnormal screening PSA 
result for each of the commonly-used PSA thresholds of >2.5 ng/ml, >4.0 ng/ml and >6.5 
ng/ml (REF. 96). Another study examined the effect of use of statins, thiazide diuretics and 
nonsteroidal anti-inflammatory drugs on PSA levels in a cohort of 1,864 men ≥40 years of 
age from the National Health and Nutrition Examination Survey that had no history of 
prostate cancer, prostatitis or recent prostate manipulations. The investigators found that 
statin use was inversely correlated to PSA levels (P = 0.01) and that men who had been 
using statins for ≥5 years had a 13% reduction in PSA levels97.
The observation that statin use results in reduced PSA levels at screening seems to indicate 
that these reduced PSA levels would diminish biopsy rates in statin users and use of statins 
would, therefore, be associated with a decreased incidence of total prostate cancer. If this 
hypothesis was true, prostate cancer diagnoses would be delayed and statin users would have 
an increased incidence of advanced prostate cancer. However, as the vast majority of studies 
found a reduced risk of advanced disease in statin users, a substantial bias introduced by the 
effect of statins on PSA levels is unlikely.
One could also argue that statin users might be more health conscious and might make more 
frequent visits to their health care provider compared with nonusers. This behaviour might 
make statin users more likely to be diagnosed with prostate cancer of an early stage 
compared with nonusers. Early detection of prostate cancer and subsequent early treatment 
is associated with less frequent progression to advanced disease stages. Overall, these 
relationships might explain the reduced risk of advanced prostate cancer observed in statin 
users. However, a number of studies reported that adjusting for the intensity of PSA 
screening did not affect the association between statin use and risk of advanced 
disease76,98,99. The most recent meta-analysis, published in 2012, reported that the findings 
of studies which controlled statistical models for potential confounding introduced by 
differing rates of PSA screening between statin users and nonusers did not greatly differ 
from the findings of studies that did not consider differences in PSA screening83 In addition, 
PSA testing is performed much more rarely in Europe compared with the USA, which 
makes the case-control studies set in Denmark18 and Finland10 relatively free from this 
potential bias100. Yet, these studies also observed a significant reduction in the risk of 
advanced prostate cancer, similar to the studies from the USA. Hence, although the potential 
for screening-related detection biases should be considered, studies taking into account 
differences in PSA screening frequency between statin users and nonusers (in addition to 
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studies in populations with coherently different PSA screening frequencies) support a true 
association between statin use and reduced risk of advanced prostate cancer.
Combination with prostate cancer therapies
In addition to the potential chemopreventive effect of statins, investigators are beginning to 
study whether statin use can improve the outcome of patients receiving established prostate 
cancer therapies.
One study in 938 men treated with brachytherapy compared the outcomes of 191 men taking 
statins with those of nonusers101. Statin users had smaller prostate volumes, lower PSA 
values and lower tumour volume in their biopsy specimens compared with nonusers. A trend 
was found that statin use was associated with improved prostate-cancer-specific and overall 
survival, but this association was not statistically significant. A different study in 1,171 men 
with stage T1–3 prostate cancer treated with radiotherapy included 382 men who were 
taking a statin at the time of diagnosis and found that statin use was a significant predictor of 
improved 5-year PSA-failure-free survival (P= 0.002)102. Oh et al.103 retrospectively 
examined the association between use of statins and risk of biochemical recurrence in 247 
men with prostate cancer treated with permanent 125I brachy-therapy, with a median follow-
up period of 51 months. In this study, statin use was associated with a significant delay in 
biochemical disease recurrence (P= 0.03). Furthermore, a meta-analysis of 13 studies that 
examined the effect of statin use on biochemical recurrence following local treatment with 
radical prostatectomy or radiotherapy found that statin use was associated with a statistically 
significant improvement in recurrence-free survival in patients who underwent radiotherapy 
(six studies; HR 0.68; 95% CI 0.49–0.93), but not in patients who underwent radical 
prostatectomy (seven studies; HR 1.05; 95% CI 0.90–1.24)104.
Taken together, these results suggest that statin use slows the progression of prostate cancer 
in men undergoing radiation treatment, possibly by sensitizing the cells to radiotherapy, but 
further research is needed to confirm these findings. One hypothesis states that statins might 
radiosensitize prostate tumour cells by causing cell cycle arrest in the late G1 phase, which is 
the stage at which cells are most sensitive to radiation-induced cell death105.
In addition, some evidence suggests that a beneficial effect of statin use in men who have 
received treatment might not be limited to radiotherapy. A retrospective study with a median 
follow-up period of 76 months in a cohort of 1,146 men that had never received statins 
before radical prostatectomy found that postoperative use of statins was associated with a 
36% reduction in the risk of PSA recurrence (P=0.004)106. Furthermore, a study comparing 
pre-operative and postoperative use of statins in 2,137 Korean men who underwent radical 
prostatectomy between 1998 and 2011 found that postoperative statin use prolonged 
recurrence-free survival over a median follow-up period of 32 months, especially in patients 
with high-risk disease (Gleason score ≥7; HR 0.27; 95% CI 0.13–0.59; P= 0.001), but 
preoperative statin use did not change pathological outcomes107. Finally, one study with a 
median follow-up time of 70 months reported that statin use significantly prolonged time to 
progression in 926 men receiving androgen deprivation therapy, even after adjusting for 
known prognostic factors such as biopsy-based Gleason score, type of primary therapy and 
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presence of metastases at initiation of androgen deprivation (HR 0.83; 95% CI 0.69–0.99; 
P= 0.04)108.
Statins have also been evaluated for their ability to reduce common adverse effects of local 
prostate cancer treatment, such as erectile dysfunction. Investigators prospectively examined 
the effect of statins on recovery of erectile function after radical retropubic prostatectomy in 
a randomized controlled trial including 50 men without hypercholesterolaemia who never 
used statins109. They found that postoperative treatment with a statin resulted in accelerated 
recovery of erectile function. Statin users had a significantly improved score in the 5-item 
International Index of Erectile Function (IIEF-5) tool at 6 months after surgery compared 
with nonusers (P = 0.003), and 55% of statin users versus 26% of nonusers had recovered 
erectile function by this time point109. This result is in agreement with a meta-analysis 
published in 2014 of 11 prospective randomized clinical trials that found that randomization 
of men without prostate cancer to receive statins resulted in a clinically relevant 
improvement in erectile function, indicated by a 3.4-point improvement on the IIEF-5 scale 
(P = 0.0001), even after adjusting for two potential confounding factors (average age of 
study participants and level of LDL cholesterol)110.
Future perspective
Successful completion of the Prostate Cancer Prevention Trial (PCPT), the Reduction by 
Dutasteride of Prostate Cancer Events (REDUCE) and the Selenium and Vitamin E Cancer 
Prevention Trial (SELECT) demonstrates that participants can be recruited for large prostate 
cancer primary prevention trials. Evidence is accumulating that supports a role for statins in 
reducing prostate cancer risk, especially advanced prostate cancer. Thus, the question arises 
whether a trial of similar size should be launched to test the efficacy of statins in the primary 
prevention of prostate cancer. We strongly believe that a trial of this nature should not yet be 
initiated.
First, our understanding of the many potential molecular mechanisms through which statins 
might prevent development and progression of cancer is still far from complete. Deciphering 
these mechanisms will help guide statin clinical trials with appropriate intermediate end 
points, as well as enable us to identify novel anticancer pathways that could inform the 
development of next-generation prostate cancer therapeutics. In addition, understanding the 
mechanisms that link cholesterol and prostate cancer will lead to the identification of tumour 
biomarkers that can indicate response to statins and enable clinicians to prescribe statin 
therapy to those patients who are predicted to show a tumour response.
Second, which type of statin would be most appropriate for use in a clinical trial is currently 
unclear. Simvastatin is the most commonly used statin in the vast majority of 
epidemiological studies that report an inverse association between statin use and risk of 
advanced prostate cancer, potentially supporting the use of simvastatin in prostate cancer 
trials. Future epidemiological studies with sufficient sample size should investigate the 
effects of different statin types on prostate cancer risk and progression or, at least, report the 
frequency of the use of different statin types in their populations.
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Two major obstacles to a primary prevention statin trial are readily foreseeable. First, as the 
prevalence of statin use is so great, finding eligible nonusers who would enrol in such a trial 
and stay in the placebo arm without becoming statin users at later stages would be a 
considerable challenge. Second, diagnosis of advanced prostate cancer is a relatively rare 
occurrence in the current era of PSA screening. As statins seem to be most strongly linked 
with a reduced risk of this form of the disease, the number of men that would need to be 
randomized and the duration of follow-up monitoring required to detect a difference in 
advanced disease incidence would be very high.
Much can be learned without launching an expensive, large and time-consuming primary 
prevention trial. For example, a strong impetus exists to begin analysing the role of statins in 
secondary and tertiary prevention. Whether statin use improves outcomes in men who have 
already been diagnosed with prostate cancer is not fully elucidated. Statin use seems to not 
affect the risk of localized prostate cancer. However, epidemiological evidence supports an 
effect of statin use in delaying disease recurrence and reducing prostate-cancer-specific 
mortality, regardless of disease characteristics at diagnosis. These findings provide a 
rationale for secondary prevention trials in all men with prostate cancer. Late stage 
castration-resistant or metastatic prostate cancer is a disease of short duration and outcome 
events occur in a time span of a few months to 1–2 years. Accordingly, from an 
epidemiological standpoint, more meaningful results from much smaller sample sizes and 
after shorter trial durations can be extrapolated from studying the effect of statin use at this 
disease stage in comparison with early-stage prostate cancer. In this setting, much could be 
learned about the biological actions of statins.
Earlier in the development of prostate cancer, studying men who undergo primary treatment 
would also yield information on how statins interact with current treatment modalities and 
might identify factors that predict response, for example, changes in lipid profiles following 
the start of statin use. In men on active surveillance protocols, particularly those at highest 
risk of disease progression, statins could be tested as an adjuvant therapy to reduce or delay 
the need for subsequent treatment, and tumour response could be monitored using tumour 
imaging111. Indeed, targeting cancer prevention at populations at high-risk of disease has 
been suggested as a way to improve the risk:benefit ratio of giving medications with 
potential adverse effects as preventive agents112; however, statins are considered to be well 
tolerated drugs with few major adverse effects.
Future drugs against prostate cancer could be used separately or in combination with statins 
to reduce prostate cancer mortality and/or morbidity. Clinical trials to investigate treatment 
with statins in combination with other agents are warranted, particularly combinations with 
compounds that show synergy with statins in animal models and whose mechanism of 
synergistic activity is known. Indeed, a study published in 2015 in 767 diabetic men with 
prostate cancer undergoing radical prostatectomy found that combined treatment with statins 
and metformin, but neither statin nor metformin use alone, resulted in a significantly 
reduced risk of biochemical recurrence during a follow-up period of 27 months (P = 0.037 
for combined statin and metformin use, P = 0.676 for statin use alone and P= 0.117 for 
metformin use alone)113. Liver X receptor agonists are a group of other potential candidates 
for combination treatments with statins. These agents stimulate cholesterol efflux from 
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cancer cells, thus, reducing intracellular cholesterol levels and inducing apoptosis43. 
Through this mechanism, these agents might act synergistically with statins to inhibit 
prostate cancer growth.
Conclusions
Increasing evidence is being published that supports the hypothesis that statin use is 
associated with a reduced risk of advanced prostate cancer. Determining causality from 
observational studies is difficult, but these epidemiological data are also supported by a 
multitude of preclinical studies that show that statins directly inhibit prostate cancer 
development and progression in cell-based and animal-based models. Thus, ample 
justification exists to proceed with further population-based and basic research. The results 
from these studies will bolster the current rationale for a primary prevention trial as well as 
targeted clinical trials with mechanistic end points. At present, we still need to further 
elucidate the benefits of statins before we can advocate that all men at risk of prostate cancer 
start statins regardless of their cholesterol profile. However, the use of statins in secondary 
and tertiary prevention to improve therapeutic outcomes in men who have already been 
diagnosed with prostate cancer might become reality in the not too distant future.
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• Statins are a commonly prescribed class of medications that lower serum 
cholesterol levels by inhibiting HMG-CoA reductase, the rate-limiting 
enzyme for cholesterol synthesis in the liver
• Preclinical research shows that statins can inhibit prostate cancer growth 
through cholesterol-mediated and non-cholesterol-mediated mechanisms (for 
example, lipid-raft-mediated and Ras signalling, respectively) that affect 
pathways essential for cancer formation and progression
• Of >30 observational studies on statin use and prostate cancer risk published 
to date, most support the hypothesis that statin use reduces the risk of 
advanced prostate cancer
• Increased PSA screening and health-conscious behaviour in statin users might 
bias some findings but are unlikely to fully explain the inverse association 
between statin use and prostate cancer risk
• Statin use also seems to be associated with improved prostate-cancer-specific 
survival, particularly in men undergoing radiotherapy, suggesting a role for 
statins in secondary and tertiary prostate cancer prevention
• Before conducting primary prevention trials, further research into the 
mechanisms contributing to reported inverse associations is required; 
however, secondary and tertiary prevention trials in men diagnosed with 
prostate cancer might soon be performed
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Figure 1. Statin use, high cholesterol and prostate cancer deaths in the USA
Age-adjusted US prostate cancer-specific mortality peaked in 1993 at 39 deaths per 100,000 
men and has since been declining114. The percentage of US men ≥20 years of age with high 
total serum cholesterol (≥240 mg/dl per National Cholesterol Education Program 
guidelines115) has also declined, from 19% in 1987 to 12% in 2012(REFS 21,116). This 
reduction coincided with increasing prevalence of statin use (~26% of US adults ≥40 years 
of age in 2011–2012)2,116. Currently, seven statin drugs are being marketed in the USA. 
Lovastatin was the first agent to be approved by the FDA in 1987. The newest agent, 
pitavastatin, was approved in 2009. *Data of statin use before 2011–2012 relates to US 
adults aged ≥45 years116, data for 2011–2012 relates to US adults aged ≥40 years2.
Alfaqih et al. Page 20













Figure 2. Mechanisms of prostate cancer growth affected by the mevalonate pathway
Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway 
that results in the synthesis of cholesterol and isoprenoids. Cholesterol is the sole precursor 
for sex steroid biosynthesis and has been shown to increase tumour androgen signalling and 
stimulate tumour growth in mouse models of prostate cancer. In addition, cholesterol is a 
key component of lipid rafts, which facilitate intracellular signalling processes by serving as 
organizing centres for the assembly of signalling molecules, such as the epidermal growth 
factor (EGF) and IL-6. EGF and IL-6 activate the PI3K AKT and JAK–STAT pathways, 
respectively, enhancing the transcription of genes involved in cholesterol homeostasis. The 
mevalonate pathway can also support prostate tumour growth via non-cholesterol-mediated 
mechanisms. For example, resulting isoprenoids, such as farnesyl pyrophosphate and 
geranyl pyrophosphate, facilitate recruitment of G-proteins Ras and Rho to the plasma 
membrane. High mevalonate levels suppress levels of the cyclin-dependent kinase inhibitor 
1 (p21), thereby promoting cell cycle progression via activation of cyclin-dependent kinase 2 
(CDK2) activity. SREBPs, sterol-regulatory-element-binding proteins.
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Figure 3. Effects of statin use during the clinical course of prostate cancer
The clinical course of prostate cancer can be followed using measurements of serum PSA 
levels, serving as a marker of tumour burden. Rising PSA levels indicate prostate cancer 
growth and clinical diagnosis. Primary therapy (for example, surgery or radiation) causes a 
rapid drop in PSA level, showing tumour removal or eradication. Prostate cancer recurrence 
is detected by rising PSA level after primary treatment. Subsequent androgen deprivation 
therapy initially results in a reduction in tumour burden and PSA level but most patients 
eventually develop castration-resistant prostate cancer. Currently, castration-resistant disease 
cannot be cured and these patients will eventually die of their disease. Statins have been 
shown to have a protective role at various stages of the clinical course of prostate cancer.
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Table 1
Pharmacological characteristics of statin medications2,14,15
Statin type Rate of use* (%) Solubility IC50 for HMG-CoA reductase (nM) Systemic bioavailability (%)
Simvastatin 42.0 Lipophilic 11.2 <5
Atorvastatin 20.2 Lipophilic 8.2 ~14
Pravastatin 11.2 Hydrophilic 44.1 17
Rosuvastatin 8.2 Hydrophilic 5.4 ~20
Lovastatin 7.4 Lipophilic 2.7–11.1 <5
Pitavastatin NR Lipophilic 6.8 >60
Fluvastatin NR Lipophilic 27.6 24
*
Rate of use in US adults aged ≥40 years reporting to take a cholesterol-lowering medication in the past 30 days (2011–2012).
IC50, half maximal inhibitory concentration; NR, not reported.
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